08:00 , Jan 5, 2009 |  BC Week In Review  |  Company News

ArQule, Daiichi Sankyo, Roche deal

ArQule and Daiichi signed their previously announced deal to co-develop and co-market ArQule's ARQ 197 to treat cancer (see BioCentury, Nov. 17, 2008). Separately, Roche declined to exercise its option under a 2004 deal to...
07:00 , Apr 21, 2008 |  BC Week In Review  |  Clinical News

ARQ 761: Phase I start

This year, ArQule will begin a U.S. Phase I trial of IV ARQ 761. Roche has an option to license worldwide rights to ArQule's E2F transcription factor 1 (E2F1) program after Phase II testing. ArQule...